UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Radiopharma startup Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Ther
